Related Experiment Videos
Comparison of mycophenolate mofetil and azathioprine in obstructive nephropathy
Aysun K Bayazit1, Yildirim Bayazit, Aytul Noyan
1Department of Pediatric Nephrology, Cukurova University School of Medicine, 01330 Adana, Balcali, Turkey. ayskar@yahoo.com
Abstract:
The effect of mycophenolate mofetil (MMF) and azathioprine (AZA) in reducing renal interstitial fibrosis in rats with unilateral ureteral obstruction (UUO) was studied. Fifty-nine rats with surgically induced UUO received oral MMF (n=19), AZA (n=19), or no treatment (n=21). The obstructed kidneys were analyzed by histology and morphometry on days 21 and 60 post UUO. Fibronectin- and collagen-stained areas were significantly lower in both treatment groups when compared with the control group 21 days post surgery. Transforming growth factor (TGF)-beta expression was significantly lower in the MMF-treated group than in the AZA-treated (P<0.01) and the control (P<0.001) groups. There was no significant difference in TGF-beta expression between the AZA-treated and the control groups 21 days post surgery (P>0.05). No significant difference was found in TGF-beta and fibronectin expression between treated and untreated groups on the 60th day post surgery. However, collagen expression was significantly lower in both treated groups than in the untreated group on the 60th day (P<0.005). We observed that MMF is more effective in preventing fibrosis than AZA in the UUO model in the short term; however, there is a less significant anti-fibrotic effect of these drugs in long-term than in short-term obstruction.
Insights
Mycophenolate mofetil (MMF) and azathioprine (AZA) reduce kidney fibrosis in rats with unilateral ureteral obstruction (UUO). MMF showed a stronger short-term effect, but both drugs had diminished long-term anti-fibrotic impact.
Area of Science:
- Nephrology
- Pharmacology
- Immunology
Background:
- Renal interstitial fibrosis is a key factor in chronic kidney disease progression.
- Unilateral ureteral obstruction (UUO) is a common model for studying kidney fibrosis.
- Immunosuppressants like MMF and AZA are used to manage kidney diseases.
Purpose of the Study:
- To investigate the efficacy of mycophenolate mofetil (MMF) and azathioprine (AZA) in mitigating renal interstitial fibrosis.
- To compare the short-term and long-term anti-fibrotic effects of MMF and AZA in a rat UUO model.
Main Methods:
- Surgically induced unilateral ureteral obstruction (UUO) in 59 rats.
- Oral administration of MMF (n=19), AZA (n=19), or no treatment (control, n=21).
- Histological and morphometric analysis of obstructed kidneys at 21 and 60 days post-UUO, assessing fibronectin, collagen, and TGF-beta expression.
Main Results:
- Both MMF and AZA significantly reduced fibronectin and collagen expression at 21 days post-UUO compared to controls.
- MMF significantly decreased TGF-beta expression at 21 days, more so than AZA or controls.
- At 60 days, collagen expression remained lower in both treatment groups, but TGF-beta and fibronectin differences diminished.
Conclusions:
- MMF demonstrates superior short-term efficacy over AZA in reducing renal fibrosis in the UUO model.
- The anti-fibrotic effects of both MMF and AZA are more pronounced in the short term than in the long term.
- These findings suggest a time-dependent role for these immunosuppressants in managing kidney fibrosis.